标题
Lanreotide autogel in acromegaly – a decade on
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 15, Issue 18, Pages 2681-2692
出版商
Informa Healthcare
发表日期
2014-10-11
DOI
10.1517/14656566.2014.970173
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
- (2014) G. Lombardi et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
- (2013) Akira Shimatsu et al. ENDOCRINE JOURNAL
- Effects of Lanreotide Autogel on Growth Hormone, Insulinlike Growth Factor 1, and Tumor Size in Acromegaly: A 1-Year Prospective Multicenter Study
- (2013) Roberto Attanasio et al. Endocrine Practice
- A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy
- (2013) Anand K. Annamalai et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
- (2013) Philippe J. Caron et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
- (2013) Roberto Salvatori et al. Pituitary
- A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly
- (2012) Richard Kay et al. CLINICAL ENDOCRINOLOGY
- Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
- (2012) S. Tuvia et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacodynamic Modeling of the Effects of Lanreotide Autogel on Growth Hormone and Insulin-Like Growth Factor 1
- (2011) María J. Garrido et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
- (2011) Yasemin Tutuncu et al. Pituitary
- Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal
- (2010) Renata S Auriemma et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
- (2010) Aart-Jan van der Lely et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR
- (2010) J. Schopohl et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- A Consensus on Criteria for Cure of Acromegaly
- (2010) A. Giustina et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Current therapy and drug pipeline for the treatment of patients with acromegaly
- (2009) Sampath Satish Kumar et al. ADVANCES IN THERAPY
- A Single-Center Open-Label Study to Investigate the Efficacy and Safety of Repeated Subcutaneous Injections of Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide
- (2009) Phillip Kelly et al. Endocrine Practice
- The German ACROSTUDY: past and present
- (2009) M Buchfelder et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Guidelines for Acromegaly Management: An Update
- (2009) S. Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
- (2009) Gherardo Mazziotti et al. Pituitary
- Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
- (2009) Roberto Salvatori et al. Pituitary
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
- (2009) Shlomo Melmed et al. Pituitary
- Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48weeks in patients with acromegaly
- (2008) Philippe Chanson et al. CLINICAL ENDOCRINOLOGY
- Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
- (2008) Annamaria Colao et al. CLINICAL ENDOCRINOLOGY
- Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects
- (2008) Iñaki F Trocóniz et al. CLINICAL PHARMACOKINETICS
- A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
- (2008) I M Holdaway et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
- (2008) Giselle F Taboada et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
- (2008) Robert D. Murray et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Molecular Origin of the Self-Assembly of Lanreotide into Nanotubes: A Mutational Approach
- (2007) Céline Valéry et al. BIOPHYSICAL JOURNAL
- Mortality in Acromegaly: A Metaanalysis
- (2007) O. M. Dekkers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now